Zydus receives final approval from USFDA for Methenamine Hippurate Tablets USP, 1 gram

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Methenamine Hippurate Tablets USP, 1 gram (USRLD: Hiprex® Tablets, 1 gram).

Methenamine Hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. Methenamine Hippurate tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad.

Methenamine Hippurate tablets had annual sales of USD 32.6 mn in the United States (IQVIA MAT January 2025).

The group now has 419 approvals and has so far filed 483* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 882.55 as compared to the previous close of Rs. 889.00. The total number of shares traded during the day was 21192 in over 1753 trades.

The stock hit an intraday high of Rs. 897.20 and intraday low of 880.00. The net turnover during the day was Rs. 18830474.00.

(*As on 31st December, 2024.)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals MethenamineHippurateTablets